---
schema_version: "secwatch.filing_event.v1"
accession: "0001759425-24-000037"
form_type: "8-K"
ticker: "MIRM"
cik: "0001759425"
company_name: "Mirum Pharmaceuticals, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:04:33.871484+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Mirum Q3 net product sales $90.3M (+89% YoY); raises FY 2024 guidance to $330-335M

## Summary
- LIVMARLI net sales $59.1M; CHOLBAM/CHENODAL combined $31.2M.
- Cash & investments $293.8M vs $286.3M at Dec 2023; OpEx $103.1M incl $18M non-cash.
- PDUFA date for chenodiol in CTX set for Dec 28, 2024.
- Volixibat granted breakthrough therapy designation for PBC; interim data at AASLD.
- In-licensed PDE4D inhibitor MRM-3379 for Fragile X syndrome; Phase 2 expected in 2025.

## SEC filing metadata
- accession: 0001759425-24-000037
- form_type: 8-K
- ticker: MIRM
- cik: 0001759425
- company_name: Mirum Pharmaceuticals, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759425/000175942524000037/0001759425-24-000037-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759425/000175942524000037/mirm-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001759425-24-000037
- JSON: https://secwatch.observer/filing/0001759425-24-000037.json
- Plain text: https://secwatch.observer/filing/0001759425-24-000037.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.